thr-687
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03666923)
Timeline
Indications
Mechanism of action
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05063734 | Phase 2 | Aug 27, 2021 | Oxurion NV. |
| NCT03666923 | Phase 1 | Sep 30, 2018 | Oxurion NV. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oxurion NV. | For profit | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1